Hikma Pharmaceuticals's gross profit for the
six
months ended in Dec. 2024 was $659 Mil. Hikma Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $1,415 Mil.
Hikma Pharmaceuticals PLC gross margin has been in long-term decline. The average rate of decline per year is -1.8%.
Hikma Pharmaceuticals Gross Profit Historical Data
The historical data trend for Hikma Pharmaceuticals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hikma Pharmaceuticals's Gross Profit
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,415 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hikma Pharmaceuticals had a gross margin of 42.30% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Hikma Pharmaceuticals Gross Profit Related Terms
Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKMPY has been successfully added to your 